Hikma Sets Injectables Sights On France, Spain and Canada

High-Containment Plant Adds Needed Capacity

With added steriles capacity coming online, Hikma is looking soon to expand its Injectables business unit into France and Spain. The company is also considering options for marketing injectable drugs in Canada.

Spain_France_Flags
France and Spain are priority countries for Hikma's Injectables expansion strategy • Source: Shutterstock

Hikma Pharmaceuticals intends in the near future to expand its European Injectables business into France and Spain, thereby ensuring a presence in Europe’s ‘big five’ markets through its existing presence in Germany, Italy and the UK. Furthermore, aided by enhanced manufacturing capacity, the company is assessing options to leverage its European and US injectables portfolio and pipeline by setting up a sales and marketing function in Canada.

Speaking exclusively to Generics Bulletin, the president of Hikma’s Injectables division, Riad Mishlawi acknowledged that Hikma’s presence in the European...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin